ACCORDING TO EVIDENCE-BASED, SUBSPECIALTY SOCIETY RECOMMENDATIONS

BOTOX® may be offered to patients after failure of 1 anticholinergic1,2

A patient’s readiness to move from an anticholinergic to BOTOX® may occur after at least 1 of the following:

AUA/SUFU Guideline

BOTOX® may be offered after 1 pharmacologic treatment failure1

AUGS/ACOG Opinion

Recommend BOTOX® as second-line treatment for OAB in appropriate patients2

Most payers require no more than 1 OAB medication failure before BOTOX®3

According to 2020 data:

72%

of patients have insurance policies that do not require trying a second oral OAB medication before BOTOX®3

97%

of total insured lives don’t require Myrbetriq® before BOTOX®3,*

*Failure after 1 anticholinergic.

  • 95% of Medicare-covered lives require ≤ 1 oral OAB medication failure3
  • 64% of commercially insured lives require ≤ 1 oral OAB medication failure3

A Reimbursement Business Advisor (RBA) can help explain BOTOX® payer policies in your area.

Failure rates are often high with oral medications4,5

Bringing up BOTOX® at the first visit helps patients consider something different rather than cycling on OAB medications after 1 anticholinergic failure when visiting an OAB specialist3

Defining OAB oral medication treatment failure

OAB medication failure occurs after at least 1 of the following:

LACK OF TREATMENT RESPONSE1
 

Still having too many leakage episodes

Not achieving treatment goals

INTOLERABLE/BOTHERSOME SIDE EFFECTS6,7
SAFETY CONCERNS8,9
SWIPE

Dry mouth

Constipation

Hypertension

Cognitive impact/dementia

Drug–drug interactions

LACK OF TREATMENT
RESPONSE1

INTOLERABLE/
BOTHERSOME
SIDE EFFECTS6,7

INTOLERABLE/BOTHERSOME
SIDE EFFECTS6,7

SAFETY
CONCERNS8,9

Still having too many leakage episodes

Dry mouth

Cognitive impact/dementia

Not achieving treatment goals

Constipation

Drug–drug interactions

 

Hypertension

 

AUA/SUFU recommend a 4- to 8-week trial of OAB medication to determine treatment failure.1

IN MULTIPLE STUDIES

Anticholinergics have been linked to an increased risk of dementia in older OAB patients10-13

According to a 2019 JAMA article:

≥ 3 years of anticholinergic use was associated with

65%

increased risk of dementia in OAB patients aged ≥ 55 years13
(N = 25,642)

Next Page